Netherlands· NL-28147c67e707
Ivemend 150 mg poeder voor oplossing voor infusie
A aprepitant product containing fosaprepitantdimeglumine, registered in Netherlands by Merck Sharp & Dohme B.V.. The same ATC class is registered in 17 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Aprepitant is registered in 17 of 19 countries.
Countries holding a registration under ATC A04AD12 (aprepitant), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Aprepitant · ATC A04AD12
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aprepitant costs, country by country.
Normalised to the WHO defined daily dose (165 mg), the median price runs from $0.40 in Finland to $157.48 in United States — a ×394 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Aprepitant · price per daily dose (165 mg)
USD · FX 28 Sept 2026
- US United States$157.48 (acquisition cost)
- CH Switzerland$73.26
- FR France$33.15
- FI Finland$0.40
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- FOSAPREPITANTDIMEGLUMINE
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Netherlands (NL)
- ATC code
- A04AD12
- ATC class
- Aprepitant
- Defined daily dose
- 165 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/07/437
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
583 interactions on record for aprepitant.
Graded by severity as the source publishes them — 73 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aprepitant · interactions on record
583 records
- 73 severe
- 380 moderate
- 25 minor
- 104 info
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- LonafarnibA16AX20severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aprepitant in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainFOSAPREPITANT ACCORD 150 MG POLVO PARA SOLUCION PARA PERFUSION EFGAccord Healthcare S.L.U.
- NorwayFosaprepitant accordAccord
- GermanyFosaprepitant AmaroxAmarox Pharma Gmbh
- United KingdomFosaprepitant 150mg powder for solution for infusion vialsAmarox Ltd
- SwedenFosaprepitant Accord 150 mg Pulver till infusionsvätska, lösningAccord Healthcare B.V.
- CanadaEMEND IVMERCK CANADA INC
- United StatesfosaprepitantMylan Institutional LLC
- SwitzerlandIvemend
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Austria · Fosaprepitant Accord, Fosaprepitant Hikma
- Germany · Fosaprepitant Amarox, Fosaprepitant Hikma
- Spain · Fosaprepitant Accord, Fosaprepitant Hikma
- Finland · Fosaprepitant Accord
- United Kingdom (Northern Ireland) · Fosaprepitant Accord Healthcare, Fosaprepitant Amarox
- Iceland · Ivemend
- Italy · Fosaprepitant Accord, Fosaprepitant Hikma
- Liechtenstein · Ivemend
- Norway · Fosaprepitant Accord, Ivemend
- Portugal · Fosaprepitant Accord, Fosaprepitant Farmoz
- Sweden · Fosaprepitant Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b3924d12-61f5-48fe-98bb-8a66053b078a GET /v1/drugs/b3924d12-61f5-48fe-98bb-8a66053b078a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ivemend-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Aprepitant",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp106500",
"excipients": [
"DINATRIUMEDETAAT 2-WATER",
"LACTOSE 0-WATER",
"NATRIUMHYDROXIDE (E 524)",
"POLYSORBAAT 80 (E 433)",
"STIKSTOF (HEAD SPACE) (E 941)",
"ZOUTZUUR (E 507)"
],
"substances": [
"FOSAPREPITANTDIMEGLUMINE"
],
"leaflet_url": null,
"authorised_at": "2010/08/31",
"procedure_number": "EMEA/H/C/000743",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/07/437",
"additional_monitoring": "N"
}See everything about aprepitant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.